Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

Cancer

Volumn 118, Issue 14, 2012, Pages 3599-3606

  Giglio, Pierre ^a,c   Dhamne, Megha ^a   Hess, Kenneth R ^b   Gilbert, Mark R ^a   Groves, Morris D ^a   Levin, Victor A ^a   Kang, Sanghee L ^a   Ictech, Sandra E ^a   Liu, Vivien ^a   Colman, Howard ^a,d   Conrad, Charles A ^a   Loghin, Monica ^a   De Groot, John ^a   Yung, W K Alfred ^a   Puduvalli, Vinay K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

anaplastic glioma; irinotecan; progression free survival; thalidomide

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CHLOROQUINE; ERLOTINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; ISOTRETINOIN; LOMUSTINE; PROCARBAZINE; SORAFENIB; TEMOZOLOMIDE; THALIDOMIDE; TIOGUANINE; VORINOSTAT;

ADULT; AGED; ANAPLASTIC GLIOMA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN SURGERY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OLIGODENDROGLIOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; UROSEPSIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE; YOUNG ADULT;

EID: 84863321033     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26663     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. (Pubitemid 40349501)
2. Cohen MH, Shen YL, Keegan P, Pazdur R,. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14: 1131-1138.
3. Stewart LA,. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359: 1011-1018. (Pubitemid 34286538)
4. Dehais C, Laigle-Donadey F, Marie Y, et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006; 107: 1891-1897. (Pubitemid 44582960)
5. Puduvalli VK, Sawaya R,. Antiangiogenesis-therapeutic strategies and clinical implications for brain tumors. J Neurooncol. 2000; 50: 189-200. (Pubitemid 32166301)
6. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M,. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001; 51: 41-45. (Pubitemid 32321900)
7. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000; 18: 708-715. (Pubitemid 30106600)
8. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ,. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2008; 112: 2038-2045. (Pubitemid 351574080)
9. Cloughesy TF, Filka E, Nelson G, et al. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002; 25: 204-208. (Pubitemid 34293080)
10. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17: 1516-1525. (Pubitemid 29220860)
11. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS,. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009; 11: 80-91.
12. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005; 103: 329-338. (Pubitemid 40129293)
13. Puduvalli VK, Giglio P, Groves MD, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008; 10: 216-222.
14. Kuhn JG,. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Williston Park). 2002; 16 (8 suppl 7): 33-40.
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280. (Pubitemid 20195640)
16. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578. (Pubitemid 29368260)
17. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009; 72: 1601-1606.
18. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999; 17: 2762-2771. (Pubitemid 29415233)
19. Chamberlain MC, Glantz MJ,. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol. 2008; 89: 231-238.
20. Brandes AA, Tosoni A, Cavallo G, et al. GICNO. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006; 24: 4746-4753. (Pubitemid 46630938)
21. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003; 21: 2299-2304. (Pubitemid 46621867)
22. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007; 9: 354-363. (Pubitemid 47169667)
23. Walbert T, Gilbert MR, Groves MD, et al. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol. 2011; 102: 273-280.
24. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007; 83: 53-60. (Pubitemid 46647165)
25. Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009; 91: 183-189.
26. Reardon DA, Quinn JA, Rich JN, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004; 6: 134-144. (Pubitemid 38455760)
27. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008; 14: 7068-7073.
28. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-1259. (Pubitemid 46424067)
29. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010; 12: 1300-1310.
30. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-787.
31. Chamberlain MC, Johnston S,. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009; 115: 1734-1743.
32. Chamberlain MC, Johnston S,. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009; 91: 359-367.
33. Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 2011; 50: 630-635.
34. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011; 29: 986-993.
35. Miller KC, Padmanabhan S, Dimicelli L, et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006; 47: 2339-2343. (Pubitemid 44768427)
36. Marras LC, Geerts WH, Perry JR,. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000; 89: 640-646. (Pubitemid 30640111)
37. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997; 33: 1592-1596. (Pubitemid 28123480)